Valsartan prevents gefitinib-induced lung inflammation and oxidative stress, modulates plasma metabolites in rats, and attenuates gefitinib-induced cardiac hypertrophy in rat by modulating angiotensin II-mediated oxidative stress and the JNK/P38 pathway (Nie et al., 2012; Tao et al., 2023). Here, MAPK8 is linked to cardiac hypertrophy.